IRIS
LUISETTI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.548
AS - Asia 5.420
EU - Europa 4.295
SA - Sud America 663
AF - Africa 159
Continente sconosciuto - Info sul continente non disponibili 85
OC - Oceania 54
AN - Antartide 1
Totale 18.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.373
CN - Cina 2.743
SG - Singapore 1.191
IE - Irlanda 931
UA - Ucraina 779
DE - Germania 526
HK - Hong Kong 524
BR - Brasile 484
FI - Finlandia 476
VN - Vietnam 431
RU - Federazione Russa 383
SE - Svezia 269
FR - Francia 251
GB - Regno Unito 250
IT - Italia 207
IN - India 94
CA - Canada 82
ZA - Sudafrica 76
BD - Bangladesh 67
AR - Argentina 60
AU - Australia 51
MX - Messico 51
JP - Giappone 48
IQ - Iraq 44
BE - Belgio 34
EC - Ecuador 34
NL - Olanda 32
PK - Pakistan 32
ES - Italia 27
PT - Portogallo 27
IR - Iran 26
VE - Venezuela 26
TR - Turchia 25
CL - Cile 23
PL - Polonia 21
CO - Colombia 20
ID - Indonesia 20
SA - Arabia Saudita 19
PH - Filippine 18
UZ - Uzbekistan 17
EG - Egitto 15
MY - Malesia 15
AT - Austria 14
KE - Kenya 14
CZ - Repubblica Ceca 13
KR - Corea 13
LT - Lituania 12
TN - Tunisia 12
TW - Taiwan 12
IL - Israele 11
MA - Marocco 11
JO - Giordania 10
JM - Giamaica 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
AZ - Azerbaigian 8
KZ - Kazakistan 8
PY - Paraguay 8
DZ - Algeria 6
GT - Guatemala 6
LB - Libano 6
TH - Thailandia 6
CH - Svizzera 5
ET - Etiopia 5
EU - Europa 5
LV - Lettonia 5
OM - Oman 5
CR - Costa Rica 4
HR - Croazia 4
HU - Ungheria 4
MU - Mauritius 4
NG - Nigeria 4
NI - Nicaragua 4
NP - Nepal 4
PE - Perù 4
BG - Bulgaria 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
GR - Grecia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
SN - Senegal 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
CY - Cipro 2
GH - Ghana 2
HN - Honduras 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MM - Myanmar 2
PR - Porto Rico 2
RO - Romania 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
Totale 18.127
Salva come PNG Salva come JPEG
Città #
Jacksonville 954
Dublin 929
Chandler 927
San Jose 663
Nanjing 641
Ashburn 591
Singapore 559
Hong Kong 504
Beijing 384
Dallas 382
Boardman 307
Council Bluffs 254
Nanchang 231
Princeton 199
Lawrence 192
Shenyang 192
Wilmington 173
Lauterbourg 170
Hebei 163
Changsha 158
Ho Chi Minh City 155
Jiaxing 148
Ann Arbor 147
Los Angeles 146
Hangzhou 105
Medford 102
Hanoi 99
Helsinki 93
Tianjin 92
Shanghai 81
Moscow 75
New York 74
Redondo Beach 70
Buffalo 63
Santa Clara 61
Johannesburg 55
Woodbridge 52
Milan 46
Munich 46
São Paulo 43
Houston 38
Norwalk 37
The Dalles 36
Tokyo 36
Brussels 32
Frankfurt am Main 31
Orem 29
Falls Church 28
Kunming 27
Piscataway 27
Seattle 27
Atlanta 26
Brooklyn 26
Chicago 26
Washington 26
Fairfield 25
Haiphong 25
Des Moines 23
London 23
Melbourne 23
Verona 23
Chennai 22
Da Nang 22
Denver 22
Toronto 22
Montreal 21
Baghdad 19
Dearborn 19
Rio de Janeiro 19
Stockholm 19
Warsaw 19
Mexico City 18
Phoenix 18
San Francisco 17
Tappahannock 17
Boston 16
Zhengzhou 16
Columbus 15
Manchester 15
Tashkent 15
Quito 14
Karachi 13
Rome 13
Santiago 13
Turku 13
Amsterdam 12
Jinan 12
Brasília 11
Coimbra 11
Guangzhou 11
Nairobi 11
Belo Horizonte 10
Brisbane 10
Changchun 10
Dhaka 10
Fuzhou 10
Guayaquil 10
Hải Dương 10
Pavia 10
Riyadh 10
Totale 11.495
Salva come PNG Salva come JPEG
Nome #
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. 596
Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. 239
Immune Activation in α-1antitrypsin Deficiency Emphysema: Beyond the Protease/Antiprotease Paradigm. 206
Abnormalities of Esophageal Motor Activity Are Highly Prevalent in Lung Transplanted Patients 166
Alpha1-antitrypsin in serum determined by capillary isoelectric focusing 165
Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis. 164
"The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. 157
Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency. 146
Capillary electrophoresis with laser-induced fluorescence detection as a novel sensitive approach for the analysis of desmosines in real samples. 146
Effects of 3'-hydroxyfarrerol (IdB 1031), a novel flavonoid agent, on phagocyte products 144
Separation of closely related peptide substrates of human proteinases by micellar electrokinetic chromatography with anionic and nonionic surfactants. 143
Assessment and management of pulmonary alveolar proteinosis in a reference center. 141
Advances in proteomic techniques for biomarker discovery in COPD 140
Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. 139
Alpha-1 antitrypsin deficiency in Italy: regional differences of the PIS and PIZ deficiency alleles. 136
Familial elevation of serum angiotensin converting enzyme activity. 134
A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis 132
A novel pharmacological approach for paraquat poisoning in rat and A549 cell line using ambroxol, a lung surfactant synthesis inducer. 128
The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? 125
A national program for detection of alpha 1-antitrypsin deficiency in Italy. Gruppo I.D.A. 124
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1. 124
Activity of different proteases in a complex mixture and 'in vitro' study of their reciprocal interferences by micellar electrokinetic chromatography. 124
Inhibition of human neutrophil elastase by erythromycin andflurythromycin, two macrolide antibiotics. 122
alpha 1-antitrypsin TAQ I polymorphism and alpha 1-antichymotrypsin mutations in patients with obstructive pulmonary disease. 122
Ambroxol and pulmonary toxicity induced by antineoplastic drugs. 122
Capillary electrophoresis as a modern tool for determining proteolytic activities in purified specimens and in real samples 121
Factors influencing oxidative imbalance in pulmonary fibrosis: an immunohistochemical study. 118
HLA markers in sarcoidosis. 118
A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. 118
Studies of MR 889, a new synthetic proteinase inhibitor. 118
Some properties of the alkaline proteinase from Aspergillus melleus. 118
Causal and synthetic associations of variants in the SERPINA gene cluster with alpha1-antitrypsin serum levels. 118
Identification and characterisation of eight novel SERPINA1 null mutations. 115
A fast amplification-reverse hybridization assay kit to detect the most frequent deficient variants in the alpha-1-antitrypsin gene. 114
Micellar electrokinetic chromatographic and capillary zone electrophoretic methods for screening urinary biomarkers of human disorders: a critical review of the state-of-the-art. 113
Micellar electrokinetic chromatography for the determination of urinary desmosine and isodesmosine in patients affected by chronic obstructive pulmonary disease 112
C reactive protein and alpha1-antitrypsin: relationship between levels and gene variants. 112
Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. 111
The cystic fibrosis gene is not likely to be involved in chronic obstructive pulmonary disease. 110
Inherited alpha1-antitrypsin deficiency: Is the level the key message? 109
EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. 109
Micellar electrokinetic chromatography: a convenient alternative to colorimetric and high performance liquid chromatographic detection for monitoring protease activity. 108
Incomplete expression of epithelial-mesenchymal transition markers in idiopathic pulmonary fibrosis. 108
Association between markers of emphysema and more severe chronic obstructive pulmonary disease. 107
Alpha1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. 107
A novel method for rapid genotypic identification of alpha 1-antitrypsin variants. 107
Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. 106
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. 106
Complement receptor 1 gene polymorphisms in sarcoidosis. 106
Interactions between SERPINA1 PiMZ genotype, occupational exposure and lung function decline. 106
MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. 105
Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. 104
Alpha-1 antitrypsin deficiency: from Italy to the world. 104
Protease-antiprotease imbalance: local evaluation with bronchoalveolar lavage. 102
The Hermansky-Pudlak syndrome. A case with macrophage-neutrophil alveolitis. 102
[American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency]. 102
Mechanisms of lung injury in cystic fibrosis. 101
Study of functional and biochemical indicators of subclinical lung damage in bleomycin-treated patients. 100
α₁-Antitrypsin level and pheno/genotypes 100
Surfactant apoprotein A modulates interleukin-8 and monocyte chemotactic peptide-1 production 98
Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. 98
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma 98
Alpha 1-antitrypsin variants produced by recombinant DNA: differences in elastase inhibitory activity and resistance to oxidant agents. 98
Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. 97
Identification of a novel alpha1-antitrypsin null variant (Q0Cairo). 97
Proteomic analysis of exhaled breath condensate from single patients with pulmonary emphysema associated to alpha1-antitrypsin deficiency. 97
Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. 97
Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease. 96
The role of bronchial epithelial cells in the pathogenesis of COPD in Z-alpha-1 antitrypsin deficiency. 96
HLA Class I, II and III polymorphisms in sarcoidosis. 95
SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 95
Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study. 94
High performance capillary electrophoresis in the study of proteinase activity and of markers of lung destruction. 93
On the activity of MR 889, a new synthetic proteinase inhibitor. 92
Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence. 91
Micellar Electrokinetic Chromatography with Laser Induced Detection and liquid chromatography tandem mass-spectrometry-based desmosine assays in urine of patients with Chronic Obstructive Pulmonary Disease: A comparative analysis. 91
The Rapid FEV(1) Decline in Chronic Obstructive Pulmonary Disease Is Associated with Predominant Emphysema: A Longitudinal Study. 90
COPD: no gene left unturned 90
Biochemical and functional markers of lung damage after bleomycin treatment. 90
Lung cancer in young adults. 89
Call for an international survey on therapeutic lavage for pulmonary alveolar proteinosis. 89
Urinary desmosine excretion in acute exacerbations of COPD: a preliminary report. 89
Clinical phenotypes of Italian and Spanish patients with α1-antitrypsin deficiency. 89
You may say that I ain't free--but it don't worry me. 88
Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESI-Q-TOF. 88
Interactions of P 1507, a new antioxidant agent, with phagocyte functions. 87
Polymorphism of angiotensin-converting enzyme gene in sarcoidosis. 86
Interactions of alpha-1-antichymotrypsin, alpha-1-proteinase inhibitor, and alpha-2-macroglobulin with the fungal enzyme, seaprose. 86
Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. 85
In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages. 85
Sarcoidosis of the thyroid: report of a case and a review of the literature. 85
Respiratory Proteomics Today: Are Technological Advances for the Identification of Biomarker Signatures Catching up with Their Promise? A Critical Review of the Literature in the Decade 2004–2013. 85
Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. 84
Secondary outputs of alpha1-antitrypsin deficiency targeted detection programme. 84
Early response of gene clusters is associated with mouse lung resistance or sensitivity to cigarette smoke. 84
Whole lung lavage therapy of pulmonary alveolar proteinosis: a global survey of current practices and procedures 84
Italian registry of patients with alpha-1 antitrypsin deficiency: General data and quality of life evaluation 84
HLA and sarcoidosis: new pathogenetic insights. 83
Introduction: the history of the Alpha One International Registry (A.I.R.). 83
Serum levels and genotype distribution of α1-antitrypsin in the general population. 83
Totale 11.493
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.566
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.566
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022704 0 0 5 16 17 26 22 60 49 10 126 373
2022/20232.658 284 184 19 225 319 276 0 153 1.061 22 71 44
2023/2024955 102 180 43 67 109 199 14 50 8 68 73 42
2024/20252.422 80 225 70 121 51 89 83 249 559 83 244 568
2025/20265.565 366 379 710 647 632 281 1.098 187 484 462 195 124
2026/2027513 138 305 70 0 0 0 0 0 0 0 0 0
Totale 18.225